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Advances in Emerging Therapies 2006
Kennedy R. Lees, MD, FRCP; Jesse Dawson, MRCP
The past year has seen further advancement toward thegoal of effective and multifaceted stroke treatment.
Encouraging evidence has emerged to support mechanical
intervention for large artery occlusion, late and imaging-
directed thrombolytic therapy, neuroprotectant strategies and
decompressive surgery for large middle cerebral artery
(MCA) stroke. We have seen important advances with regard
to secondary preventative strategies.
The attraction of catheter-based reperfusion techniques is
obvious. They may afford use of lower systemic doses of
thrombolytic agents, while mechanical clot disruption and
retrieval could obviate the need for drugs. This would not
only be a particular advantage in those with elevated hemor-
rhage risk but may also improve the poor reperfusion rates
after proximal carotid, basilar or M1 MCA occlusion. Al-
though the MERCI trial1 suggested benefit some 2 years ago,
this position has been supported by a recent small series of 12
patients with basilar artery occlusion2 of whom half under-
went successful mechanical recanalization. Time to reperfu-
sion was shorter in these patients and they were spared the
risks of thrombolytic therapy. Preliminary data also suggest
that catheter-based interventions can be applied more distally
than hitherto considered possible, perhaps offering direct
treatment for intracranial stenosis with reduced rates of stroke
or vascular death compared with historical controls.3 Al-
though these techniques are hugely promising and may
represent a real alternative for those with major stroke who
are unsuitable for recombinant tissue plasminogen activator
(rt-PA), we must recognize that conclusive randomized con-
trolled evidence is lacking and benefit is unproven. Further-
more, such techniques will only aid those fortunate enough to
be treated in a major center. While we consider these
complex, costly and less readily available treatments, we
should note that 2006 provided further evidence that intrave-
nous thrombolytic therapy is safe but underused4 and that it
remains a valuable treatment for life-threatening conditions
such as basilar artery occlusion.5
Trials such as ECASS III and the International Stroke
Trial-3 are still testing whether the time window for
thrombolytic therapy can be safely prolonged to 4.5 or
perhaps 6 hours. Preliminary evidence suggests that use of
magnetic resonance perfusion/diffusion scanning will allow
us to stretch the window at least this far. MRI is the more
widely studied modality but CT perfusion–imaging also
identifies ischemic penumbra.6 Recently published nonran-
domized data7 showed that favorable outcomes were more
common after MRI guided rt-PA within 6 hours than in
historical trial controls given rt-PA treatment or placebo after
standard CT imaging. Reassuringly, the intracerebral hemor-
rhage rate was comparable to that after placebo.
The Desmoteplase study program suggests that this newer
fibrin-specific thrombolytic may be effective up to 9 hours
after ictus in patients with MRI perfusion/diffusion mismatch.
The DIAS (Desmoteplase in Acute Ischemic Stroke) trial
reported nearly 2 years ago,8 but the DEDAS (Dose Escala-
tion of Desmoteplase for Acute Ischemic Stroke) trial9 and a
combined analysis of the two10 now appear to corroborate the
initial findings: reperfusion rates and clinical outcomes were
improved in such patients if treated with 90 to 125 g/kg of
desmoteplase. A further phase IIb study (DIAS II) seeks to
replicate these results while allowing a choice of MRI or CT
perfusion as entry criterion. By selecting those patients most
likely to benefit from thrombolytic therapy, the investigators
hope that the risk benefit ratio can be further refined, while
also maximizing its use. However, we must remain cautious:
the data supporting CT perfusion and MRI-guided rt-PA do
not yet derive from randomized controlled trials, and the
desmoteplase data are based on a tiny patient cohort. We are
well aware of the limitations of small trials; even relatively
large and rigorously controlled trials can give misleading
results.
Reperfusion strategies have been the cornerstone of acute
stroke treatment since introduction over a decade ago.
Throughout this period a number of promising neuropro-
tectant drugs have been tried, tested and failed. The year 2006
appeared different; evidence emerged that NXY-059, a novel
free radical trapping agent, may reduce poststroke disability
and the rate of hemorrhagic transformation after rt-PA.11 In
line with expectations for this approach, the benefits seen
were modest but by no means economically, clinically or
statistically insignificant especially in light of potentially
wide applicability. A lively debate ensued. A particular focus
of attention was the novel analysis method used, which was
geared to measure improvement in disability across the entire
range of modified Rankin scores. It seems remarkable that
such methods that increase rigor and trial power are still
criticized in favor of less sensitive dichotomized approaches
designed instead for treatments that could threaten to increase
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the proportion of disabled survivors. The neutral results of the
confirmatory SAINT II trial that were recently announced in
summary format suggest that intravenous administration of a
free-radical–trapping agent may not be effective after all; we
await publication of the full results. Despite this grave
disappointment, the debate and the lessons learned will be of
value in the future because rigorous science is a prerequisite
to development of emerging therapies.
Complete MCA infarction is an evil among the stroke
subtypes and is associated with brain edema, increased
intracranial pressure and a risk of transtentorial herniation
and death. Medical therapy does little to improve mortality
rates, which reach 80%. Several case series and systematic
reviews suggest that decompressive hemicraniectomy can
reduce mortality,12 perhaps to as low as 30%. However, a
major concern has been that surgery may simply convert a
fatal ischemic stroke event into a severely disabling one, with
little hope of a favorable outcome. Some time ago, the
DESTINY (Decompressive Surgery for the Treatment of
Malignant Infarction of the Middle Cerebral Artery) trial13
showed a significant mortality reduction in those with severe
MCA stroke after surgery compared with standard conserva-
tive treatment (46.7% versus 88.2%), but the functional
outcome data are only recently available.14 These suggest that
functional outcomes are improved with a higher proportion of
patients having a modified Rankin Scale score of 3; a
message reinforced by the recently concluded DECIMAL
trial (Decompressive Craniectomy in Malignant Middle Ce-
rebral Artery Infarcts).15 DECIMAL included 38 patients—
slightly more than the 32 in DESTINY—and again showed a
large mortality benefit and improved functional outcome after
surgery; (52.8% absolute mortality risk reduction and 50%
compared with 22% had a modified Rankin Scale score of3
at 12 month). Hemicraniectomy should perhaps now be
considered for patients with complete MCA infarction, and
certainly the results of the combined analyses of these 2 trials
are eagerly awaited.
Although these changes are encouraging, we took bigger
strides with secondary prevention. Three large trials (ESPRIT,
CHARISMA and SPARCL) have contributed usefully.
ESPRIT16 involved 2763 patients with recent stroke or
transient ischemic attack and revealed, during a mean
follow-up of 3.5 years, that the combination of aspirin and
slow-release dipyridamole afford a 20% relative risk reduc-
tion in the rate of vascular death or nonfatal stroke or
myocardial infarction. The surprising lack of increased bleed-
ing complications is curious, and further claims of anti-
inflammatory and nonplatelet-mediated benefits of dipyri-
damole have emerged.17 The results of ESPRIT confirm those
of ESPS 218 and have consolidated the position of aspirin and
dipyridamole combination therapy as the antiplatelet strategy
of choice for secondary prevention of stroke.
Regrettably, dual aspirin and clopidogrel therapy has had a
less good year. The CHARISMA trial19 compared aspirin and
clopidogrel therapy versus aspirin alone among 15 603 pa-
tients, the majority of whom had established cardiovascular
disease. In 27% of patients the trial entry criterion was
previous cerebrovascular disease. Clopidogrel was no more
effective than placebo in aspirin-treated patients with stable
cardiovascular disease, but bleeding complications were in-
creased. Trends toward benefit were apparent in those who
entered the trial on account of stroke, and all-cause stroke
appeared lower in the population as a whole. However,
benefits only bordered on statistical significance before ad-
justment for multiple comparisons and do not support the
combination as a routine treatment strategy.
We know that statin therapy reduces both the risk of stroke
in patients with coronary artery disease and the risk of cardiac
events in those who have had a stroke. It was not clear,
however, whether statin therapy reduces the risk of recurrent
stroke after an index cerebrovascular event. The SPARCL
trial20 randomized 4731 patients to high dose atorvastatin or
placebo. Treatment led to a 16% relative risk reduction of
recurrent stroke and to reductions in the rates of most other
vascular complications. The incidence of hemorrhagic stroke
was slightly higher but fatal intracerebral hemorrhage was
unchanged. Thus, in contrast to results from the Heart
Protection Study, where rate of recurrent stroke was unaltered
by simvastatin treatment, the SPARCL trial confirms that risk
of recurrent stroke is significantly reduced by statin therapy.
So what do these developments tell us? The cynics might
say not much. We have long known that thrombolytic therapy
is effective and more so the earlier it is given. We have also
long suspected that the therapeutic window may be extended,
that surgery may be of benefit in those with the most severe
strokes, that aspirin and dipyridamole dual therapy is prefer-
able to aspirin monotherapy and that statin therapy is of
benefit after stroke. However, many questions have been
answered and answered clearly. The publication of random-
ized controlled trials involving over 20 000 patients is hardly
insignificant. These have clarified the roles of several treat-
ment strategies. Our biggest disappointment is of course that
the once shining star of neuroprotectant therapy burns a little
less brightly, but even this provides testament to the ability of
the stroke community to conduct the highest quality of
randomized controlled trials. We hope this will continue into
2007 and beyond with the emergence of more promising
therapies.
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